Skip to content

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

News

Select Year
Clinical Trials
Search …

April 1, 2026

Oncolytics Biotech® Completes Domicile Change to the United States

March 19, 2026

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

March 2, 2026

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

February 24, 2026

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

February 4, 2026

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

January 15, 2026

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

January 14, 2026

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

January 12, 2026

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

January 9, 2026

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

January 8, 2026

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Page 2 of 71

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

Our Mission
Leadership
Board of Directors
Careers
Contact

Science

Our Science
Pipeline
Resources

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent

Copyright © 2026 Oncolytics Biotech Inc.